The chances of a solid tumor spreading to the brain vary depending on the cancer. Around 30% of cancer patients see their cancer spread to their brains, which is challenging to cure. Approximately 200,000 new brain metastases are identified in the United States each year. About 20% of lung tumors migrate to the brain within a year of diagnosis. This percentage can be as high as 7% in people with breast cancer, renal cell cancer, or melanoma. This is in addition to the patients who had brain metastases when they were first diagnosed.
New treatment guidelines for malignancies that have progressed to the brain have been brought forth. The development is a considerable contribution to the Brain Tumor Therapeutics Market. The guidelines are expected to improve patient care and help many people live longer, healthier lives. The American Society of Clinical Oncology convened an expert council to develop new guidelines set. A panel of leading cancer specialists and a patient advocate participated in the discussion.
The guidelines reflect significant advancements in treating brain metastases (cancers that have spread to the brain) in recent decades. In the 1970s, efforts were made to create guidelines focusing mainly on steroids and whole-brain radiation therapy. However, it was not a controlled, randomized study that was used to recommend the use of surgery and chemotherapy.
The new recommendations are significantly more comprehensive and evidence-based than the previous ones. They will assist doctors and patients in making the most effective treatment choices and achieving the best results.
Local therapy (surgery or stereotactic radiosurgery) for symptomatic brain metastases is emphasized in the guidelines. Further, when these choices are possible are also outlined. Depending on the tumor kind and molecular traits, they identify circumstances in which local therapy or whole-brain radiotherapy can be used instead of chemotherapy, targeted therapy, or immunotherapy. They also show how, in many situations, clinicians can avoid whole-brain radiotherapy's cognitive toxicity. This can be achieved by utilizing stereotactic radiosurgery or hippocampal-avoidant whole-brain radiotherapy with the medication memantine.
Patients with brain metastases may be referred to a neurosurgeon, radiation oncologist, or medical oncologist for treatment. The rigorous analysis underpinning these guidelines will provide each subspecialist with a comprehensive picture of the treatment options customized to a patient's needs. The outcome would lead to patients being equipped to choose the best-personalized approach. Thus, helping them maximize long-term control of brain metastases while maintaining good functional results.
Related Reports:
Global Brain Biopsy Needles Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026
Global Brain Monitoring Devices Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
Global Brain Implants Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
Global Brain Computer Interface Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026
